Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (590)	10/6/1999 8:31:00 PM
From: Carter Berezay	Read Replies (1) \| Respond to of 792

Sean, you are a fountain of information!!! Congratulations to you for finding that link and letting us all know about it. I think it's great that MBI 226 is their acne drug. It makes total sense. MBI 226 kills all bacteria on a patient's skin. Why not use it as an acne drug? In my mind 226 could be moved to Phase III right after the current Phase II trials are successfully completed. As one threader has mentioned to me there is no reason the current drug trials could not be completed in one month's time. That would allow for Phase III testing to start in Jan/Feb of 2000 on the blood poisoning-prevention end. If 226 could be moved to Phase III testing for curing acne MBI would have a minimum of 2 drugs in Phase trials at the same time. This does not count their eye drug and the as-yet unspecified drug I'm so curious to know about. Thanks again for your sleuthing work. Every new piece of information fits into the grid somewhere. Carter B.